ОбзорГрафикНовостиTraderScreen

HSBC Knock-Out LLY/  DE000HE0XN24  /

Stuttgart
13.11.2024  17:42:52 Изменение-0.10 Бид13.11.2024 Предложение13.11.2024 Базовый актив Цена исполнения Дата истечения Тип опциона
1.59EUR -5.92% 1.59
Величина цены спроса: 20,000		 -
Величина цены предложения: -		 Eli Lilly and Co 649.403 USD 31.12.2078 Call
TeleTrader 30.10 Eli Lilly's Q3 revenue up 20% to $11.4 billion
TeleTrader 02.10 Eli Lilly to commit $4.5 billion in a new Indiana facility
Newsfile Corp 16.09 Kalm Therapeutics Hires Former GSK Director Dr. Tomoko Maeda-Chubachi as Chief Medical Officer
TeleTrader 09.09 Eli Lilly appoints Lucas Montarce as CFO
Newsfile Corp 28.08 The GLP-1 Products and Players - Expanding a new Era of Pharmaceutical Products for Diabetes and Wei...
GlobeNewswire 27.08 Boehringer Ingelheim and Eli Lilly and Company Join American Kidney Fund’s 2024 Corporate Membership...
GlobeNewswire 26.08 Eliem Therapeutics Announces Additions to its Leadership Team
GlobeNewswire 21.08 Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Co...
GlobeNewswire 21.08 Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Co...
GlobeNewswire 14.08 Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer’s ...
GlobeNewswire 14.08 Abeona Therapeutics® Announces Appointment of Bernhardt Zeiher, MD, FCCP, FACP, and Eric Crombez, MD...
GlobeNewswire 08.08 CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire 08.08 Calling All Morphic Holding, Inc. (MORF) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Cl...
TeleTrader 08.08 US opens higher with data, earnings in focus
GlobeNewswire 08.08 ProQR Announces Second Quarter 2024 Operating and Financial Results
TeleTrader 08.08 Eli Lilly's Q2 revenue jumps 36% to $11.3B
GlobeNewswire 08.08 Defiance Launches LLYX, the First 2X Leveraged Single-Stock ETF on Eli Lilly
GlobeNewswire 07.08 Aclaris Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
GlobeNewswire 06.08 Lucrative Incentive for Biotechs as Global Alzheimer's Disease Therapeutics Market Forecasted to Rea...
GlobeNewswire 06.08 SEED Therapeutics (SEED) Enters into Strategic Research Collaboration with Eisai Co., Ltd. to Discov...
GlobeNewswire 02.08 Calling All Morphic Holding, Inc. (MORF) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Cl...
GlobeNewswire 01.08 Merus Announces Financial Results for the Second Quarter 2024 and Provides Business Update
GlobeNewswire 01.08 COUR Pharmaceuticals Announces Leadership Transition for Strategic Growth Objectives
GlobeNewswire 01.08 Compass Pathways announces second quarter 2024 financial results and business highlights
GlobeNewswire 31.07 SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PFC, HMNF, MORF on Behalf of Shareholders